key: cord-0901000-oiioe7fg
authors: Graham, M. S.; May, A.; Varsavsky, T.; Sudre, C.; Murray, B.; Klaser, K.; Antonelli, M.; Canas, L.; Molteni, E.; Modat, M.; Drew, D. A.; Nguyen, L.; Rader, B.; Hu, C.; Capdevila, J.; Hammers, A.; Chan, A.; Wolf, J.; Brownstein, J.; Spector, T.; Ourselin, S.; Steves, C.; Astley, C.
title: Knowledge barriers in the symptomatic-COVID-19 testing programme in the UK: an observational study
date: 2021-03-17
journal: nan
DOI: 10.1101/2021.03.16.21253719
sha: 69c49e021d3ca69a88cd05554704020e287e5631
doc_id: 901000
cord_uid: oiioe7fg

Background Symptomatic testing programmes are crucial to the COVID-19 pandemic response. We sought to examine United Kingdom (UK) testing rates amongst individuals with test-qualifying symptoms, and factors associated with not testing. Methods We analysed a cohort of untested symptomatic app users (N=1,237), nested in the Zoe COVID Symptom Study (Zoe, N= 4,394,948); and symptomatic survey respondents who wanted, but did not have a test (N=1,956), drawn from the University of Maryland-Facebook Covid-19 Symptom Survey (UMD-Facebook, N=775,746). Findings The proportion tested among individuals with incident test-qualifying symptoms rose from ~20% to ~75% from April to December 2020 in Zoe. Testing was lower with one vs more symptoms (73.0% vs 85.0%), or short vs long symptom duration (72.6% vs 87.8%). 40.4% of survey respondents did not identify all three test-qualifying symptoms. Symptom identification decreased for every decade older (OR=0.908 [95% CI 0.883-0.933]). Amongst symptomatic UMD-Facebook respondents who wanted but did not have a test, not knowing where to go was the most cited factor (32.4%); this increased for each decade older (OR=1.207 [1.129-1.292]) and for every 4-years fewer in education (OR=0.685 [0.599-0.783]). Interpretation Despite current UK messaging on COVID-19 testing, there is a knowledge gap about when and where to test, and this may be contributing to the ~25% testing gap. Risk factors, including older age and less education, highlight potential opportunities to tailor public health messages.

Evidence before this study To assess current evidence on test uptake in symptomatic testing programmes, and the reasons for not testing, we searched PubMed from database inception for research using the keywords (COVID-19) AND (testing) AND ((access) OR (uptake)). We did not find any work reporting on levels of test uptake amongst symptomatic individuals. We found three papers investigating geographic barriers to testing. We found one US based survey reporting on knowledge barriers to testing, and one UK based survey reporting on barriers in the period March -August 2020. Neither of these studies were able to combine testing behaviour with prospectively collected symptom reports from the users surveyed.

Added value of this study Through prospective collection of symptom and test reports, we were able to estimate testing uptake amongst individuals with test-qualifying symptoms in the UK. Our results indicate that whilst testing has improved since the start of the pandemic, there remains a considerable testing gap. Investigating this gap we find that individuals with just one test-qualifying symptom or short symptom duration are less likely to get tested. We also find knowledge barriers to testing: a substantial proportion of individuals do not know which symptoms qualify them for a COVID-19 test, and do not know where to seek testing. We find a larger knowledge gap in individuals with older age and fewer years of education.

Despite the UK having a simple set of symptom-based testing criteria, with tests made freely available through nationalised healthcare, a quarter of individuals with qualifying symptoms do not get tested. Our findings suggest testing uptake may be limited by individuals not acting on mild or transient symptoms, not recognising the testing criteria, and not knowing where to get tested. Improved messaging may help address this testing gap, with opportunities to target individuals of older age or fewer years of education. Messaging may prove even more valuable in countries with more fragmented testing infrastructure or more nuanced testing criteria, where knowledge barriers are likely to be greater.

Testing is a crucial component of the COVID-19 public health response to guide mitigation and triage illness, even as countries roll out vaccination campaigns. Whilst mass, population-based testing has been trialled, 1-3 the majority of programmes seek to test individuals experiencing a certain set of symptoms. A successful program needs high testing uptake among those with test-qualifying symptoms. 4 Achieving high uptake requires both an informed and willing population, and sufficient infrastructure to ensure test availability and accessibility.

In the United Kingdom (UK), the test-qualifying symptoms (fever, cough, or loss of smell) 5 are relatively straightforward, have been consistent since loss of smell was added to the criteria on 18 May 2020, and are buttressed by a free, high-capacity, national testing programme. This is in contrast to other countries where criteria for testing have been more nuanced, varied over time and between regions, and testing access remains suboptimal. 6 ,7 Yet, despite the strengths of the UK programme, we observed that 25% of symptom-tracking app participants do not report testing despite experiencing test-qualifying symptoms. This and other evidence 8,9 raised questions regarding how the path from symptoms to testing could be improved to fully support the pandemic response.

Prior research focuses on logistical barriers for not getting tested such as geographic, socioeconomic and structural disparities in testing access, 6,8,10 but there are other important barriers, including the knowledge required to successfully navigate the journey from symptom onset to test completion. Examining the reasons why people do not complete testing is hindered by the difficulty in identifying individuals who should have, but did not, receive COVID-19 tests.

Towards this end, we leveraged longitudinal data from over 4 million Zoe COVID Symptom Study (Zoe) participants, 11 and over 700,000 surveys from the University of Maryland-Facebook Covid-19 Symptom Survey (UMD-Facebook), to describe the temporal changes in COVID-19 testing among UK residents with test-qualifying symptoms. We followed-up with cross-sectional surveys of the untested to identify knowledge barriers along the full journey to successful testing.

This research combines syndromic surveillance data from the UK Zoe COVID Symptom Study (Zoe) 11 and the UK UMD-Facebook COVID-19 Symptom Survey (UMD-Facebook) 12 Additionally, more detailed follow-up surveys of recently untested symptomatic participants were analyzed. Survey details provided in Supplement S1-S3. Throughout we define test-qualifying symptoms using the UK's National Health Service (NHS) criteria: high temperature; new, continuous cough; or loss or change to sense of smell or taste. 5 16 . For some analyses, Zoe reports of either loss of taste/smell or altered taste/smell were combined. 16 Zoe and UMD-Facebook analyses were conducted using Python 3.8 and R 3.6.3, respectively.

The proportion of Zoe participants reporting COVID-19 testing has increased over time ( Figure  1 ), from <20% (1 April 2020) to >70% (1 January 2021). In mid-September, national PCR testing capacity was exceeded, 17 coincident with a transient drop in reported tests. In late 2020, despite adequate test capacity, >25% of test-qualifying app users did not report a test. The UMD-Facebook survey time-series mirrors these trends (Supplementary Figure 5) , albeit with a lower absolute proportion, likely due, in part, to survey design differences (e.g. ever tests and symptoms in prior 24 hours, vs tests -7 to +14 days from incident symptoms). The UMD-Facebook testing gap is generally lower amongst respondents with a smartphone, and even lower among symptom-tracking app participants (not necessarily Zoe).

To better understand the factors contributing to COVID-19 testing, Zoe participants with testqualifying symptoms during the study period, who did not report testing (N=20,425), were studied further. During this period, the Similarly, the proportion of ever-tested in UMD-Facebook was lowest among those with only one testqualifying symptom or short symptom duration (Supplementary Figure 5) . A total of 1,254 users (26.6%) responded to the follow-up survey. Zoe and follow-up survey participants during this period were younger and more female than the general population, similar to the demographic trends reported previously in Zoe 13 and other digital health studies (Supplement S6). 18, 19 Journey to Successful COVID-19 Testing

In the Zoe follow-up survey, only 42.1% survey respondents recalled having experienced at least one test-qualifying symptom in the past month (Table 2) . Of those who recalled their symptoms, 54.7% recognised that these symptoms qualified them for a COVID-19 test. Among participants who recognized test-qualifying symptoms, they were likely to go on to attempt (85.6%) and then successfully obtain a COVID-19 test (93.0%, or 18.4% of all survey respondents).

Among those who reported a single test-qualifying symptom ( 

Just 54.7% of those who recalled experiencing test-qualifying symptoms indicated their symptoms qualified them for a COVID-19 test. We queried the remaining respondents (N=809, i.e. those who did not recall or who did not indicate the symptoms they recalled qualified them for testing) which symptoms would qualify them for a test. These respondents were similarly able to recognize fever (63.4%), cough (67.6%), and loss of smell (65.4%), and much less so for altered smell (29.7%). Only 59.6% identified the triad of fever, cough, and loss of smell as qualifying for a test, with lower recognition amongst the oldest age groups (Table 4 ). In univariate analyses, each decade older reduced the odds of recognizing the triad (OR = 0.908 [95% CI 0.883 -0.933]). This finding remained largely unchanged after adjustment for sex, IMD, and rural-urban living. We found similar associations with the outcome of identifying each individual symptoms (model results in Supplement S8). No associations were found for sex, age, IMD and rural-/urban living.

In the follow-up survey, there were few respondents (N=17) who recognised their symptoms qualified them for testing, and attempted, but did not succeed at testing (Table 2) . We therefore evaluated complementary data from a subcohort of UMD-Facebook respondents from 21 December 2020 to 21 February 2021, who endorsed test-qualifying symptoms, who had never tested, and who indicated "yes" to the question question "Have you wanted to get tested for coronavirus at any time in the last 14 days?" (N=1,956, Table 5 ). Among those who wanted testing, "I don't know where to go" was the most frequently selected option (32.4%). The other multi-choice reasons were: "I am unable to travel to a testing location" (29.1%), "I tried to get a test but was not able to get one" (25.6%), "I am worried about bad things happening to me . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 17, 2021. ;  or my family (including discrimination, government policies, and social stigma)" (18.4%), "I can't afford the cost of the test" (17.9%), and "I don't have time to get tested"(13.3%). Given the scope of this study, we have focused on the knowledge-based response, though we acknowledge the logistical barriers are important.

We further investigated demographic factors associated with not knowing where to go to obtain a test (Figure 2 ). Not knowing where to go to obtain a test ("yes" vs referent "no") was were not significant with Bonferroni correction for multiple hypothesis testing (p-threshold 0.0125 = 0.05/4). Education was similarly protective for not knowing where to test adjusting for age and sex, use of survey weights, or assuming missing responses were "no" (models results in Supplementary S9).

Acknowledging our limited sample size, we conducted qualitative, hypothesis-generating analyses of other demographic factors correlated with knowledge barriers (Supplementary S10). While cities were not protective in the regression model, the proportion not knowing where to test was slightly lower in London than elsewhere (Supplementary S11). Having a smartphone and using a symptom-tracking app qualitatively had a bigger impact on the knowledge gap than the relatively small urban-rural and regional differences. There were modest qualitative differences in not knowing where to test by profession, with the highest proportions among those in transportation, tourism and construction and the lowest in finance, public administration and health.

Our analysis finds that in December 2020 approximately one quarter of symptomatic UK Zoe participants who qualified for a COVID-19 test did not undergo testing. The proportion of evertested recently-symptomatic UK UMD-Facebook respondents echoes this trend. While we show a substantial improvement from April, 2020, the persistent testing gap is problematic for pandemic management in the UK and elsewhere. Non-pharmaceutical mitigation strategies are likely to be required, [20] [21] [22] despite effective vaccines, because of COVID-19 transmissibility and the anticipated time to reach herd immunity, even with a one-dose immunization strategy. 23 The lower the proportion of identified infections, such as through insufficient testing of symptomatic cases, the more likely transmission events will go unchecked.

With this testing gap in mind, we sought to characterize barriers to testing that might inform improvements to the UK testing programme using data from two large, complementary surveillance platforms. Through analysis of prospective self-reported testing outcomes, along with follow-up and population-sampled surveys, we identified three key knowledge barriers . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 17, 2021. ;  along the path to successful COVID-19 testing. Firstly, the association of less testing with brief and/or single test-qualifying symptoms suggests an implied severity threshold for testing that is inconsistent with guidance, 5 and with the spectrum of infectious COVID-19. 24 Individuals may minimise their symptoms or possibly hold the misconceived notion that COVID-19 manifests in a stereotypical manner. 25 In a preprint DHSC report utilizing online surveys May 25 to August 5, 2020, those with test-qualifying symptoms did not request testing because symptoms were mild (16.0%), improved (16.1%), or they did not think symptoms were due to COVID-19 (20%). 8

Secondly, we show that four of ten did not recognize all three of the triad of UK test-qualifying-i.e. fever, cough and loss of smell. The DHSC report 8 estimated 51.1% of all respondents failed to recognize the triad. Despite increased media coverage and a second wave with mitigation intensification, 26 recognition of these test-qualifying symptoms in our survey around six months later increased by ~10% and therefore remains alarmingly low.

Lastly, one third of those who wanted a COVID-19 test cited not knowing where to test as a contributing factor to their not getting one. This was the most frequently cited reason among the six options. Thus, despite the fact that survey respondents are possibly more aware of health information, they acknowledge challenges to finding testing that are comparable to, if not greater than, logistical barriers to testing (e.g. travel, time), even within the framework of the more centralized UK testing programme.

Our findings have significant public health implications. The UK NHS testing programme offers free COVID-19 tests to those with test-qualifying symptoms, with the list of qualifying symptoms unchanged since loss/alteration to taste and smell were included on 18 May 2020, 27 and tests accessed through a central booking system. 5 Risk mitigation and public health principles generally would agree with these key features of the UK program i.e. the use of concise and consistent guidance, and limiting logistical barriers to following guidance. In this sense, the UK is a sort of case study of the "best case scenario", and yet there is still a significant gap in understanding. Not only are greater efforts needed to educate the UK public, it is likely that comparable efforts to mind the knowledge gap will be needed in countries with regionally varying testing criteria or methods of accessing testing.

Our work suggests there is a need for messaging improvements to the UK testing campaign. In our study, among the untested who qualified for a test, older age was associated with not knowing when and where to test. In the earlier DHSC report 8 , older age was generally protective with respect to testing knowledge and behaviors, perhaps suggesting knowledge gains in the young over the past six months. Fewer years of education was also associated with not knowing where to test in our study. We found suggestive evidence that the knowledge gap may be more pronounced among those who do not have smartphones. Older populations in pre-pandemic studies have slower adoption of certain technologies, yet the abrupt social isolation resulting from mitigation strategies may be leaving important segments of the population behind. 28 Education attained and age are likely not the root cause. Rather they likely highlight pre-existing . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 17, 2021. ;  health-information disparities that have been exacerbated by a year of unprecedented changes in how individuals interface with each other and the world.

Our findings support the need for targeted messaging to certain at-risk demographic groups, possibly in a non-digital format (e.g. radio, community signage). Our findings are particularly timely in light of work showing that expansion of the symptoms that qualify for a test would help detect more cases, assuming those who qualify do indeed successfully test. 29, 30 This theoretical gain in case detection could be lost if the change in tack leaves vulnerable populations behind. There is overlap between knowledge risk factors and COVID-19 risk, such as older age, 31 though we did see a higher absolute rate of testing in the oldest age group. Overlap with vaccine hesitancy risk factors may further amplify disparities in healthcare access, leaving some groups both less tested and less protected.

Furthermore, messaging could also emphasise that even individuals with mild or transient symptoms may have COVID-19 and should get tested. COVID-19 has a broad spectrum of disease severity with a substantial number of cases being fully asymptomatic, and with asymptomatic carriers still being able to transmit, albeit at reduced rates. 24 

The Zoe platform affords a unique opportunity to prospectively link testing behaviours with incident symptoms in a large user base comprising ~6% of the UK population. The UMD-Facebook platform, though smaller in size and slightly different in survey design, corroborates temporal trends over in the broader population. To our knowledge, this has enabled the first time-varying estimate of testing rates amongst individuals that qualify for COVID-19 tests over the course of the pandemic. Both platforms could be leveraged to track the testing and knowledge gaps, in real time, allowing the effectiveness of interventions, such as improved messaging on when and where to test, to be assessed.

We acknowledge a number of limitations to this study. Digital surveys include selected populations not necessarily representative of the wider population. Such platforms have welldocumented biases in demographic age, sex, and socioeconomic factors which we adjusted for in our analyses. 18, 32 In addition, digital surveys may not be generalizable, as they may be enriched for health-councious internet-connected participants, and thus underestimate disparities in at-risk demographic groups. We show that symptom-tracking app participants and those with smartphones have higher testing rates than all UMD-Facebook survey respondents.

Confounding and measurement bias in this observational study using self-reported covariates and outcomes may also cause us to miss other important issues related to testing. We adjusted for common confounders, and attempted to identify proxies for the knowledge gap rather than attribute causality. There is no timely, efficient trial to conduct analyses of this scale. Self-report could introduce non-differential and differential measurement error, including the possibility of some events being omitted, or recorded inaccurately or inappropriately. Furthermore, the financial implications of having to self-isolate disproportionately affect the poorest, and may increase unwillingness to test 33 and respondents may be wary of self-reporting socially . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 17, 2021. ;  stigmatized reasons for not complying with guidance. Lastly, selection can theoretically induce collider bias 34 if the exposure and outcome are both causes of participation or subpopulation selection.

Testing is a fundamental principle of population-wide transmission mitigation. While the UK now has sufficient testing capacity, consistent guidelines, and free testing for those who qualify that is coordinated centrally, still we see a 25% testing gap among those with test-qualifying symptoms. We show this gap may be driven in part by a lack of understanding of mild COVID-19, national testing criteria, and testing access, especially among the elderly and those who have had fewer years of education. We propose altering the course of the UK testing programme to address this knowledge barrier to COVID-19 testing. In addition, other countries may benefit from improved understanding of modifiable barriers.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 17, 2021. Figure 1 for . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 17, 2021. ; Figure 2 Proportion (95% confidence interval) of respondents who indicated "yes" (per "yes" plus "no") for "I don't know where to go" as a option to the question "Do any of the following reasons describe why you haven't been tested for coronavirus in the last X days?", where X is the self-reported duration of symptom capped at 14 days. This was restricted to untested respondents with test-qualifying symptoms. Proportions stratified by age (top) and education (bottom).

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 17, 2021. ; . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 17, 2021. ;  In each daily report, users are asked about any symptoms they experience that day, and any COVID-19 tests they have had.

Users are asked "How do you feel physically right now?". If they select "I'm not feeling quite right", they are presented with a symptom options checklist. The symptom options specifically analysed in this study are:

Are you experiencing any of the below symptoms?

Fever or feel too hot Loss of smell / taste Altered smell / taste (things smell or taste different to usual) Persistent cough (coughing a lot for more than an hour, or 3 or more coughing episodes in 24 hours) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 17, 2021 I did not believe I could/should get a test with my symptoms at the time My symptoms were normal / not new for me I thought that travelling to a testing appointment would be difficult or risky I was concerned about discomfort or pain from the swab I have already had Covid and did not think I could get it again I couldn't find the time to go to an appointment (e.g. couldn't get time off work/childcare) I was concerned testing positive might affect me financially (job/income/studies) I was concerned about the cost of the the test I was concerned testing positive would affect me socially (time away from friends/family) I was concerned about testing positive and being contacted by contact tracers or health authorities The tests are not reliable OTHER -free text Proceed to SURVEY END Q4 Did you receive a COVID-19 test (swab or otherwise) within 14 days of having such symptoms?

If NO, Proceed to Q4a

Please state the reason(s) the test did not happen (all that apply):

I did not know how to get a test There were no testing appointments available There were no home testing kits available The test never arrived/I never received the result back I thought that travelling to a testing appointment would be too risky I was concerned about swabbing myself/being swabbed . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 17, 2021. ;  Difficult with transportation to my appointment (e.g. too far away/I didn't have a vehicle) I couldn't find the time to go to an appointment (e.g. couldn't get time off work/childcare) I could not afford the test I was told by a doctor or testing centre that I didn't need a test OTHER -free text Proceed to SURVEY END Q5 What date was your COVID-19 test? Please also log this test through the app, if you have not done so already.

[Date entry field] Proceed to SURVEY END SURVEY END . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 17, 2021 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 17, 2021. ;  skipped/invalid -77 = seen but unanswered

Have you wanted to get tested for coronavirus Figure: Testing trends UMD Facebook UK COVID-19 Symptom Survey temporal trends in the proportion of symptomatic survey respondents ever tested from survey start (April 30, 2020). Additional questions for the never tested respondents were added in survey wave 7 and beyond (December 21, 2020, vertical grey line). Surveys with non-missing geographic region in the UK, self-reporting at least one of fever, cough or loss of smell/taste in the prior 24 hours (N=107,021, solid purple), plotting proportion (Wilson method for binomial 95% confidence intervals) who indicate ever testing for COVID-19. (a) Starting June 27, 2020, respondents were queried about technology use. There were N=67508 (63.1%, dashed green) who reported using a smartphone device, while N=16,488 (15.4%, dashed yellow) reported using any symptom tracking app. Survey-weighted mean (+/-2 standard deviation) for all surveys with testqualifying symptoms included for comparison. This was generally lower than the raw proportion ever tested. Testing proportion among cross-sectional surveys varied by (b) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 17, 2021 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 17, 2021. ; https://doi.org/10.1101/2021.03.16.21253719 doi: medRxiv preprint

On Pilot Massive COVID-19 Testing by Antigen Tests in Europe. Case Study: Slovakia

The English Indices of Deprivation 2019: technical report

Urban and Rural Area Definitions for Policy Purposes in England and Wales: Methodology. Office for National Statistics

UK Covid-19 Dashboard

Determinants of Participants' Follow-Up and Characterization of Representativeness in Flu Near You, A Participatory Disease Surveillance System

Using Facebook Advertising to Recruit Representative Samples: Feasibility Assessment of a Cross-Sectional Survey

Mask-wearing and control of SARS-CoV-2 transmission in the USA: a cross-sectional study. The Lancet Digital Health

Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis

Self-Identified Work Type: While confidence bounds are overlapping, work/profession of financial/insurance/real estate services, public administration, health, professional/scientific/technical activities were the lowest while transportation

Where living (city, town, village/rural) vs technology (none, smart phone, smart phone with tracking app). The proportion was lower among those using smart phone or symptom tracking app technology, regardless of whether living in a city

Sensitivity analyses assuming missing responses are "no", for where living (city, town, village/rural) vs technology (none, smart phone, smart phone with symptom tracking app). The absolute proportion not knowing where to go is lower when missing are assumed to be "no

The authors CMA, BR and JSB declare no competing interests. AM, JCP, CH, JW are employees of Zoe Global Ltd. TDS is a consultant to Zoe Global Ltd. DAD and ATC previously served as investigators on a clinical trial of diet and lifestyle using a separate smartphone application that was supported by Zoe Global. ATC reports grants from Massachusetts Consortium on Pathogen Readiness, during the conduct of the study; personal fees from Pfizer Inc., personal fees from Boehringer Ingelheim, personal fees from Bayer Pharma AG, outside the submitted work. DAD reports grants from National Institutes of Health, grants from MassCPR, grants from American Gastroenterological Association during the conduct of the study.

MSG, CMA, TV, and CJS conceived of the study. CMA and MSG wrote the first draft of the manuscript. MSG, AM, CH, JC oversaw acquisition of Zoe data collection. MSG, TV, CMA, ATC, TDS, SO, CJS contributed to the Zoe follow-up survey design. CMA and JSB verified the underlying UMD-Facebook data. MSG and TV verified the underlying KCL/Zoe data. CMA and MSG contributed to the analyses. All authors contributed to the interpretation of the data for the work, revised the manuscript, and approved the final manuscript.

Logistic regression models for the association of not knowing where to test, including covariates of age, sex, education and where living, comparing those who answered "yes" and "no". Further sensitivity analyses assuming missing responses to be "no" lowers the proportion of answered "yes" and attenuates p-values, while effect estimates are directionally consistent and statistically significant (e.g. education multivariate model per 4 years of education, OR=0.711 (0.619-0.813), p=8.84e-07). Modeling age as young (referent 18-54 years) vs old (55+), produced a similar estimate of the association of age (OR=2.1 (1.65, 2.69), p=2.12e-09) with not knowing where to test. Modeling education in 8-year categories starting prior to completion of secondary school (0-8, 9-16, and 17-24) was also similar OR=0.662, 0.528-0.830, p=3.65e-4). See Supplementary Figure 7 and 9 for additional sensitivity analyses and qualitative investigations. Shown are the proportion (Wilson 95% confidence interval for binomial) reporting they did not know where to test ("yes" vs "yes" and "no") across various demographic factors including: a) self-identified work type, b) where living (city,town, village/rural) vs technology used (none, smart phone, symptom tracking app). Missing responses are excluded in the primary analyses. c) Sensitivity analysis assuming missing responses are "no", and are generally lower but with the same demographic patterns.

Map of proportion of symptomatic, untested survey respondents who wanted to test but did not know where to test (a) proportion, (b) sensitivity analysis assuming missing responses were "no", and (c) number of surveys with yes or no responses to the reason "I don't know where to go" when asked "Do any of the following reasons describe why you haven't been tested for coronavirus in the last X days? [y/n]". X is the self-reported duration of symptoms (up to 14 days) and (d) . (d) Geographic distribution of proportion of symptomatic ever tested during the study period and (e) early in the pandemic (Apr-Aug 2020). Not the orange (d) and yellow (e) color scales span the same percentage but have different minimum values. Early in the pandemic the testing gap was very similar across geographic areas. During the study period, the testing gap is closing in all geographic areas, with qualitatively better testing gains in the testing rates in some areas.